Institutional Ownership
Vertex Pharmaceuticals Inc
CUSIP 92532F100COMVRTXQ1 2026
Latest EPS (Diluted)
$4.02
Q1 2026 · Mar 31, 2026
Latest Revenue
$2.99B
Reported quarter
Latest Net Income
$1.03B
Reported quarter
Quarters on Record
12
From SEC XBRL filings
Quarterly Earnings
EPS, revenue & net income · SEC XBRL (10-Q / 10-K)
| Period | Quarter | EPS (Basic) | EPS (Diluted) | Revenue | Net Income | Form |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Q1 2026 | $4.06 | $4.02 | $2.99B | $1.03B | 10-Q |
| Sep 30, 2025 | Q3 2025 | $4.24 | $4.20 | $3.08B | $1.08B | 10-Q |
| Jun 30, 2025 | Q2 2025 | $4.02 | $3.99 | $2.96B | $1.03B | 10-Q |
| Mar 31, 2025 | Q1 2025 | $2.52 | $2.49 | $2.77B | $646.30M | 10-Q |
| Sep 30, 2024 | Q3 2024 | $4.05 | $4.01 | $2.77B | $1.05B | 10-Q |
| Jun 30, 2024 | Q2 2024 | $-13.92 | $-13.92 | $2.65B | -$3.59B | 10-Q |
| Mar 31, 2024 | Q1 2024 | $4.26 | $4.21 | $2.69B | $1.10B | 10-Q |
| Sep 30, 2023 | Q3 2023 | $4.01 | $3.97 | $2.48B | $1.04B | 10-Q |
| Jun 30, 2023 | Q2 2023 | $3.55 | $3.52 | $2.49B | $915.70M | 10-Q |
| Mar 31, 2023 | Q1 2023 | $2.72 | $2.69 | $2.37B | $699.80M | 10-Q |
| Sep 30, 2022 | Q3 2022 | $3.63 | $3.59 | $2.33B | $930.50M | 10-Q |
| Jun 30, 2022 | Q2 2022 | $3.17 | $3.13 | $2.20B | $810.50M | 10-Q |